Preclinical Pharmacology Characterization of Sovleplenib (HMPL-523), an Orally Available Syk Inhibitor
The Journal of Pharmacology and Experimental Therapeutics · 2024-01 · 388 (1) · 156-170
DOI: 10.1124/jpet.123.001752 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Pharmacology and Experimental Therapeutics, 2024-01. Verfasst von Yu Cai und 15 weiteren Autor:innen. Beteiligte Einrichtung: HUTCHMED Limited, Shanghai, China yuc@hutch-med.com. Hauptthemen laut MEDLINE: Autoimmune Diseases, Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 35 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- HUTCHMED Limited, Shanghai, China yuc@hutch-med.com.
- HUTCHMED Limited, Shanghai, China.
ORCID-Profile: Yu Cai
Zitieren
APA
Cai, Y., He, J., Wu, Z., He, W., Dai, X., Xu, Y., Cheng, M., Yang, N., Ren, Y., Wang, G., Wang, J., Sai, Y., Jia, H., Dai, G., Li, X., & Su, W. (2024). Preclinical Pharmacology Characterization of Sovleplenib (HMPL-523), an Orally Available Syk Inhibitor. The Journal of Pharmacology and Experimental Therapeutics, 388(1), 156-170. https://doi.org/10.1124/jpet.123.001752
Vancouver
Cai Y, He J, Wu Z, He W, Dai X, Xu Y, et al. Preclinical Pharmacology Characterization of Sovleplenib (HMPL-523), an Orally Available Syk Inhibitor. The Journal of Pharmacology and Experimental Therapeutics. 2024;388(1):156-170. doi:10.1124/jpet.123.001752
BibTeX
@article{Cai2024,
author = {Cai, Yu and He, Jianlin and Wu, Zhipeng and He, Weigang and Dai, Xiaoming and Xu, Yan and Cheng, Min and Yang, Na and Ren, Yongxin and Wang, Guanglin and Wang, Jian and Sai, Yang and Jia, Hong and Dai, Guangxiu and Li, Xiong and Su, Weiguo},
title = {Preclinical Pharmacology Characterization of Sovleplenib (HMPL-523), an Orally Available Syk Inhibitor},
journal = {The Journal of Pharmacology and Experimental Therapeutics},
year = {2024},
volume = {388},
number = {1},
pages = {156--170},
doi = {10.1124/jpet.123.001752}
}
EUVIMED